MiR-133 is decreased in mouse and human models of cardiac hypertrophy, and has been shown to inhibit cardiac hypertrophy by targeting RhoA, Cdc42, and Nelf-A/WHSC2. Here, NELFA is linked to cardiac hypertrophy.